Over the last decade, the number of pharmaceutical benefits managers has increased, and their influence has expanded rapidly. These managers now provide prescription drug coverage to more than 100 million Americans. The effect of pharmaceutical benefits managers on health care delivery remains unclear. We review the development of these organizations, their current role in the delivery of pharmaceutical therapies to patients, and their relationship with pharmaceutical manufacturers. We discuss potential advantages and disadvantages of pharmaceutical benefits manager practices and suggest ways in which these organizations can be made more accountable to the employer groups that hire them.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of Artificial Intelligence in Drug Discovery to Revolutionize the Pharmaceutical Industry: Resources, Methods and Applications.
Recent Pat Biotechnol
January 2025
SRM Modinagar College of Pharmacy, SRM Institute of Science and Technology, Delhi NCR Campus, Modinagar, Ghaziabad, Uttar Pradesh, India.
Traditional drug discovery methods such as wet-lab testing, validations, and synthetic techniques are time-consuming and expensive. Artificial Intelligence (AI) approaches have progressed to the point where they can have a significant impact on the drug discovery process. Using massive volumes of open data, artificial intelligence methods are revolutionizing the pharmaceutical industry.
View Article and Find Full Text PDFNutritional Health Connection of Algae and its Pharmaceutical Value as Anticancer and Antioxidant Constituents of Drugs.
Recent Pat Biotechnol
January 2025
Department of Zoology, University of Education, Bank Road Campus, Lahore, Pakistan.
The marine environment is one of the major biomass producers of algae and seaweed; it is rich in functional ingredients or active metabolites with valuable nutritional health effects. Algal metabolites derived from the cultivation of both microalgae and macroalgae may positively impact human health, offering physiological, pharmaceutical and nutritional benefits. Microalgae have been widely used as novel sources of bioactive substances.
View Article and Find Full Text PDFOxyberberine alleviates lipopolysaccharide-induced intestinal barrier disruption and inflammation in human colonic Caco-2 cells .
Front Pharmacol
January 2025
Department of Pharmaceutical Sciences, Zunyi Medical University, Zhuhai, China.
Background: Oxyberberine (OBB) is a naturally occurring isoquinoline alkaloid that is believed to possess various health-promoting properties, including anti-fungus, hepatoprotection, anti-inflammation, and anti-intestinal mucositis effects. Despite several studies reporting the health benefits of OBB in treating ulcerative colitis (UC), its specific mechanism of action has yet to be fully elucidated.
Purpose: This investigation is designed to explore the potential protective efficacy of OBB and the latent mechanism using an model of UC-like inflammatory intestinal cells.
Challenges and opportunities of artificial intelligence in African health space.
Digit Health
January 2025
Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.
The application of artificial intelligence (AI) to healthcare in Africa has the potential to transform productivity, diagnosis, disease surveillance, and resource allocation by improving accuracy and efficiency. However, to fully realize its benefits, it is necessary to consider issues concerning data privacy, equity, infrastructure integration, and ethical policy development. The use of these tools may improve the detection of diseases, the distribution of resources, and the continuity of care.
View Article and Find Full Text PDFThrombolytic therapy for patients with acute ischemic stroke: systematic review and network meta-analysis of randomized trials.
Front Neurol
January 2025
Department of Pharmacy, Aerospace Center Hospital, Beijing, China.
Objective: To systematically compare the benefits and risks of all thrombolytic agents (tenecteplase, reteplase, and alteplase) at different doses for thrombolytic therapy in patients with acute ischemic stroke (AIS).
Background: Alteplase is the cornerstone treatment for AIS, but alternative thrombolytic agents are needed. The efficacy and safety of tenecteplase and reteplase, compared to alteplase, remain unclear, as does the optimal dosing for these treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!